Michael Wang, MD, reviews ASH 2025 data showing durable safety with long-term BTK inhibition, promising next-generation targeted agents, sustained CAR T-cell efficacy, and evidence favoring upfront ...
Pandorum Technologies and Nucelion Therapeutics Announce Strategic Collaboration to Manufacture Exosome-Based Tissue Regenerative Therapy for Ocular Diseases in APAC Markets Pandorum Technologies, a ...
The MarketWatch News Department was not involved in the creation of this content. SynuSight Biotech has licensed (18) F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein ...
Dren Bio, a privately held, clinical-stage biotechnology company developing first-in-class myeloid cell engager therapeutics, announced today that it has entered into a strategic collaboration with ...
– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...
Eli Lilly and Company has finalized its acquisition of Adverum Biotechnologies, a move that delivers a promising gene therapy platform for ocular diseases to the Indianapolis-based pharmaceutical ...
SHANGHAI, Oct. 31, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy ...
AI-powered vector design and preclinical validation mark the first step in a multi-phase program aimed at accelerating the path from discovery to clinical assessment in Alzheimer's disease. AUSTIN, TX ...
Cell and gene therapies (CGTs) are gaining strategic importance across the healthcare landscape, with oncology being the leading therapeutic area followed by cardiovascular and central nervous system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results